Clinical trials: Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy.
The used of reduced fluence parameters for panretinal photocoagulation decreases pain as perceived by the patient, compared to traditional parameters.
- Trial name
- NCT00802269
- Testing
- Retinal laser photocoagulation
- Where
- Mexico
- Volunteers
- 25 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Proliferative Diabetic Retinopathy
Changes in Vitreous Temperature During Phacoemulsification
Temperature in the vitreous cavity decreases during vitrectomy, and the same effect is seen during an uneventful phaco surgery. Significant changes occur between the baseline temperature and after every step of the surgery.
- Trial name
- NCT01568242
- Testing
- Phacoemlsification
- Where
- Mexico
- Sponsor
- Asociación para Evitar la Ceguera en México
Proliferative Diabetic Retinopathy
Safety and Efficacy of Low-Fluence PRP for PDR
To determine the safety and efficacy of a single session of low-fluence panretinal photocoagulation when compared to full-fluence PRP.
- Trial name
- NCT01737957
- Testing
- Low-fluence PRP with 532nm green LASER, Full-Fluence PRP with 532nm LASER
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Asociación para Evitar la Ceguera en México
PDR - Proliferative Diabetic Retinopathy
The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR)
This study aims to slow down disease progression, reduce postoperative complications and decrease retreatment frequency in subjects with proliferative diabetic retinopathy (PDR) by administering a single subretinal injection of…
- Trial name
- NCT06412224
- Testing
- RRG001
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Li Xiaorong
Non Proliferative Diabetic Retinopathy(NPDR)
Clinical Study on Prognosis of Patients With Severe NPDR Undergoing Vitrectomy
To investigate the prognosis of retinal structure and function after vitrectomy in patients with severe non-proliferative diabetic retinopathy, to explore the feasibility of vitrectomy in patients with severe non-proliferative…
- Trial name
- NCT05852132
- Testing
- pars plana vitrectomy(PPV), Pars plana vitrectomy(PPV) +Panretinal photocoagulation(PRP), Panretinal photocoagulation(PRP)
- Where
- China
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- Fei Gao
Proliferative Diabetic Retinopathy
Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy
To evaluate if intravitreal Ozurdex can reduce the incidence of recurrent vitreous hemorrhage after primary pars plana vitrectomy (PPV) in patients with proliferative diabetic retinopathy (PDRP).
- Trial name
- NCT01478737
- Testing
- Intravitreal dexamethasone implant, Vitrectomy
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Anders Kvanta
Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression
Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy
Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus (DM), while proliferative diabetic retinopathy (PDR) is the principal cause of severe visual loss in patients with diabetes.
- Conditions
- Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression, Diabetic Retinopathy
- Trial name
- PROPER (NCT04674254)
- Testing
- Bevacizumab Injection, Targeted retinal photocoagulation, Standard pan-retinal photocoagulation
- Where
- Egypt
- Volunteers
- 43 people
- Sponsor
- Cairo University
Non-proliferative Diabetic Retinopathy
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
- Trial name
- NCT05695417
- Testing
- OTX-TKI
- Where
- 10 sites in United States
- Volunteers
- 21 people
- Sponsor
- Ocular Therapeutix, Inc.
Proliferative Diabetic Retinopathy
Gas Tamponade for Prevention of Postoperative Vitreous Hemorrhage in Diabetics
Hypothesis: Patients undergoing pars plana vitrectomy for the indication of diabetic vitreous hemorrhage will have a lower incidence of postoperative vitreous hemorrhaging during the 6-month trial period when vitreous…
- Trial name
- NCT04380077
- Testing
- vitrectomy with sulfur hexafluoride gas, vitrectomy with balanced salt solution
- Where
- Mexico
- Volunteers
- 150 people
- Sponsor
- Rush Eye Associates
Neovascular Glaucoma, Proliferative Diabetic Retinopathy
A Study on the Treatment Strategy of NVG Secondary to PDR
With the increasing incidence of proliferative diabetic retinopathy (PDR), subsequent neovascular glaucoma (NVG) has become one of the main causes of blindness in PDR patients, and the intraocular pressure of PDR patients with…
- Trial name
- NCT05156021
- Testing
- anti-VEGF
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Ruijin Hospital
Proliferative Diabetic Retinopathy
OCT and OCT-A Afer Diabetic Vitrectomy in PDR
Detection of any structural or vascular changes at the macula after Pars Plana Vitrectomy ( PPV ) in cases with complicated proliferative diabetic retinopathy ( PDR )
- Trial name
- NCT05938491
- Testing
- OCT and OCT-A
- Volunteers
- 30 people
- Sponsor
- Assiut University
Proliferative Diabetic Retinopathy, Vitrectomy
Observation of the Efficacy of Different Vitrectomy Systems to Treat Proliferative Diabetic Retinopathy
In recent years, vitrectomy has moved toward a minimally invasive vitrectomy surgery (MIV) system, which could effectively reduce the occurrence of operation complications, while reducing the time of post-operation recovery.
- Trial name
- NCT05446948
- Testing
- beveled 27G+ vitrectomy system, standard 25G+ vitrectomy system
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tianjin Medical University Eye Hospital
Proliferative Diabetic Retinopathy
Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
Diabetic neovascularization refers to a type of diabetic retinopathy which is worsening by the abnormal growth of blood vessels in the back of the eye, damaging the retina.
- Trial name
- NCT00606138
- Testing
- ranibizumab, Laser photocoagulation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rush University Medical Center
Non Proliferative Diabetic Retinopathy
Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR
It is estimated that there are about 600 million diabetes mellitus (DM) patients all over the world until 2040，and almost 50% of whom have some degree of diabetic retinopathy (DR) at any given time.
- Trial name
- NCT04103671
- Testing
- Prompt panretinal photocoagulation, 25G Pars-plana vitrectomy
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Proliferative Diabetic Retinopathy
Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients
This is an unmasking randomized clinical trial. the main purpose of this study is to analyze whether posvitrectomy proactive use of conbercept can reduce the rate of postoperative complication in PDR patients.
- Trial name
- NCT05642793
- Testing
- proactive Anti-VEGF (conbercept) use, passive Anti-VEGF (conbercept) use
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University Third Hospital
Proliferative Diabetic Retinopathy, Pars Plana Vitrectomy
Establishment and Validation of a Risk Prediction Model for Long-term Low Vision After Vitrectomy in PDR Patients
Diabetic retinopathy (DR) is the main cause of blindness among working-age adults in the world. Proliferative diabetic retinopathy (PDR) is the severe stage of DR, which is characterized by neovascularization of the retina.
- Conditions
- Proliferative Diabetic Retinopathy, Pars Plana Vitrectomy, Risk Prediction Model
- Trial name
- NCT05631054
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Tianjin Medical University Eye Hospital
NPDR - Non Proliferative Diabetic Retinopathy
Characterization of Retinal Vascular Disease in Eyes With Mild to Moderate NPDR in Diabetes Type 2
Characterization of Retinal vascular disease in eyes with mild to moderate NPDR in Diabetes type 2, using novel non-invasive Imaging methods, in a longitudinal, prospective and interventional clinical Study with 2 years of…
- Trial name
- CORDIS (NCT03696810)
- Testing
- Laboratory tests
- Where
- Portugal
- Volunteers
- 141 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy
Pars-plana vitrectomy (PPV) is the cornerstone of surgical treatment for eyes with complicated proliferative diabetic retinopathy. Anti-VEGF intravitreal injection before PPV has shown a good effect on surgical outcomes.
- Conditions
- Proliferative Diabetic Retinopathy, Vitreous Hemorrhage, Tractional Retinal Detachment
- Trial name
- NCT05514925
- Testing
- Bevacizumab Injection [Avastin], Peripheral Retinal Cryoapplication
- Where
- Tunisia
- Volunteers
- 60 people
- Sponsor
- Khairallah Moncef
Proliferative Diabetic Retinopathy
The Effect of IVA for Preventing Postvitrectomy Hemorrhage in PDR
Aflibercept, a recombinant fusion antibody that binds to all subtypes of VEGF and PlGF, has been shown to induce effective regression of retinal neovascularization secondary to PDR but there had been lack of a well-structured…
- Trial name
- NCT05478967
- Testing
- IVA injection before vitrectomy
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Peking University People's Hospital
Non Proliferative Diabetic Retinopathy
Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy
This clinical trial is a multi-center, double-blind, randomized, placebo controlled , parallel design, superiority, phase 4 study to evaluate the efficacy and safety of Entelon 50mg in 396 patients with non-proliferative diabetic…
- Trial name
- NCT05358080
- Testing
- Entelon Tab. 50mg
- Where
- South Korea
- Volunteers
- 396 people
- Sponsor
- Hanlim Pharm. Co., Ltd.